期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 84, 期 3, 页码 362-369出版社
WILEY
DOI: 10.1038/clpt.2008.89
关键词
-
资金
- NCRR/NIH [1UL1 RR02497501]
Our objective was to develop a DNA biobank linked to phenotypic data derived from an electronic medical record (EMR) system. An opt-out model was implemented after significant review and revision. The plan included (i) development and maintenance of a de-identified mirror image of the EMR, namely, the synthetic derivative (SD) and (ii) DNA extracted from discarded blood samples and linked to the SD. Surveys of patients indicated general acceptance of the concept, with only a minority (similar to 5%) opposing it. As a result, mechanisms to facilitate opt-out included publicity and revision of a standard consent to treatment form. Algorithms for sample handling and procedures for de-identification were developed and validated in order to ensure acceptable error rates (<0.3 and <0.1%, respectively). The rate of sample accrual is 700-900 samples/week. The advantages of this approach are the rate of sample acquisition and the diversity of phenotypes based on EMRs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据